盐酸苯那普利药物上市后的流行病学监测  

Evaluation on the effect of Benazepril for hypertension through postmarketing surveillance

作　　者：曹卫华[1] 李立明[1] 胡永华[1] 詹思延[1] 李晓晖[1] 李芃[1] 吴涛[1] 李俊[1] 王涛[1] 

机构地区：[1]北京医科大学公共卫生学院流行病学教研室,100083

出　　处：《中华流行病学杂志》2000年第3期190-193,共4页Chinese Journal of Epidemiology

基　　金：国家"九五"攻关课题!(编号 :96 90 6 0 2 0 5)

摘　　要：目的　评价盐酸苯那普利药品在以社区为基础的原发性高血压患者人群中使用的降压效果和安全性。方法　连续收集了 1831例服用盐酸苯那普利药的原发性高血压患者的 18个月用药记录 ,包括血压水平、用药和不良反应情况等。结果　患者人群既往服药患者占 1/ 3,按规定服药和单独服用盐酸苯那普利者占 96 %以上。盐酸苯那普利的有效率从 3个月的 73.6 %上升到 18个月的84.7% ,各种特征的患者均有效。 18个月的血压下降幅度为收缩压 /舒张压 1.4/ 0 .9kPa(10 .8/ 6 .7mmHg)。 416人出现不良反应 ,发生率 2 2 .7% ,主要不良反应类型是咳嗽。首次发生不良反应的高峰出现在治疗的前 3个月内 ,轻度占近 6 0 %。结论　长期服用盐酸苯那普利的降压效果是肯定的 ,同时又是安全的。Objective To evaluate the efficacy and safety of Benazepril used among the essential hypertensives. Methods 1 831 essential hypertensive patients aged 35 to 75 were randomly selected from a community and followed for 18 months. The level of blood pressure, status of taking Benazepril and side effects were sequencially collected. Results 1/3 of the patients had taken antihypertensive drug before the study and the rate of compliance was over 96%. The effective rate of Benazepril was 73.6 % at three months and increased to 84.7 % at 18 months. Comparing with the baseline data, SBP and DBP declined 10.8 mmHg and 6.7 mmHg respectively. The rate of side effect was 22.7 %. Cough was most commonly seen among side effects. The peak of first recording on side effect occurred at three months including 60% of them mild. Conclusion Results showed that Benazepril had good efficacy and safety for the essential hypertension patients in a long term observation.

关 键 词：高血压 流行病学 盐酸苯那普利 

分 类 号：R181.3[医药卫生—流行病学]